Menu
ncarol.com
  • Home
  • Music
  • Asheville Music
  • Entertainment
  • Business
  • Real Estate
  • Technology
  • Health
  • Books
ncarol.com

Juventix Regenerative Medical PRP Highlighted in University-Published Research Study
ncarol.com/10280466

Trending...
  • Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs
  • Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration
  • ALight Technology And Services Limited Advances Through Peachscore + Dealum Accelerator and Join LvlUp Labs
Laboratory Testing for Product Validation BSR Labs Juventix PRP Study Table Juventix Packaging With Tubes Juventix Regenerative Medical, LLC
TAMPA, Fla. - ncarol.com -- Juventix Regenerative Medical, a leader in regenerative medicine solutions, proudly announces that its Platelet-Rich Plasma (PRP) technology has been featured in a groundbreaking university-published research study. The study, titled "Platelet-Rich Plasma for Rheumatoid Arthritis: A Case Series", published in the peer-reviewed journal Cureus, underscores the efficacy of Juventix PRP in managing rheumatoid arthritis, showcasing its transformative potential in clinical applications.

The study explores the use of PRP to address inflammation and improve outcomes in rheumatoid arthritis patients, with findings demonstrating measurable benefits attributed to Juventix PRP's advanced process. The research highlights the role of PRP in promoting tissue repair and reducing joint pain, offering a promising non-surgical alternative for patients seeking regenerative therapies.

Scientific Validation Backed by Laboratory Studies
Juventix PRP's inclusion in this research aligns with findings from extensive laboratory evaluations conducted by BioSciences Research Associates (2020) and Biofyl Scientific Research (2023). Key results include:
  • 84% platelet recovery, significantly enhancing platelet-derived growth factor (PDGF) concentrations.
  • 10x increase in PDGF levels, with treated PRP reaching 10,844 pg/mL compared to 1,536 pg/mL in untreated samples.
  • Minimal contamination of red and white blood cells, ensuring safety and reducing inflammatory risks.
  • Optimized pH of 7.5, creating an ideal environment for platelet activation and growth factor release.
  • Innovative activation methods, including photoactivation and bio-incubation, transforming PRP into PRF for versatile clinical applications.
"The inclusion of Juventix PRP in a peer-reviewed study underscores our commitment to delivering scientifically validated, high-quality regenerative solutions," said Lance Liberti, CEO of Juventix Regenerative Medical. "Our focus on innovation ensures practitioners can trust Juventix PRP for consistent, superior patient outcomes."

More on ncarol.com
  • Kestrel Ridge Health Launches AI-Powered Ophthalmology Workforce Forecasting Platform
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
  • Brian G. Miller Co., LLC Receives Tier 1 Ranking in the 2027 Edition of Best Law Firms®
  • The Villari Firm, PLLC Named to the 2027 Edition of Best Law Firms
  • Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration

Special Offer for Medical Practitioners
To introduce clinicians to its cutting-edge PRP systems, Juventix is offering a sample PRP kit for only $20. This limited-time opportunity enables practitioners to experience the proven quality of Juventix PRP firsthand.
• Email: hello@juventix.com with the subject line "SAMPLE"
• Visit: https://juventix.com/sample-page/

About Juventix Regenerative Medical, LLC
Founded in 2017 by Lance Liberti, Juventix Regenerative Medical has been a pioneer in non-surgical regenerative solutions, including FDA-cleared PRP kits. The company offers comprehensive products such as centrifuges, LED activators, and bio-incubators to support superior PRP preparation. Juventix also collaborates with prestigious organizations, including the University of South Florida (USF) Health Center for Advanced Medical Learning and Simulation (CAMLS), to host advanced clinical training symposiums.

For more information, visit www.Juventix.com or contact:
📞 (866) 693-4777

More on ncarol.com
  • Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs
  • ZenaTech (NAS DAQ: ZENA) $1 Million in New Utility Contracts- Potential $2.5 Million Follow-On Opportunity Puts Its Drone Business in the Spotlight!
  • New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
  • Genuine Hospitality, LLC Selected to Operate Holiday Inn Express & Suites Jacksonville – Town Center
  • Shiokly Launches Online Marketplace to Help Singapore Home-Based Businesses Sell More, With First Product Listed Free

✉️ Email:
hello@juventix.com
Restore, Revive, Regenerate – Juventix Regenerative Medical.

Media Contact
Lance Liberti
***@juventix.com
866-693-4777


Source: Juventix Regenerative Medical, LLC

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • P-Wave Press Announces Becoming Dad: Reflections for New Fathers by L. A. Davenport
  • Logicraft Launches FuelDeck™, AI That Turns Aviation Fuel Tickets Into One Traceable Ledger
  • Inaugural OC Tech Week Draws 3,000 From 12 Countries, Sends Finalist to $1M Startup World Cup
  • Award-Winning American Hotelier Opens Art-Filled Luxury Cottage in Norfolk, England
  • Young Author Taraji Jones Surpasses 100 Amazon Book Sales
  • K2 Global / Ozi Amanat Named Among Top 100 AI Venture Capitalists in 2026
  • Dr. Latorial Faison Appointed Poet Laureate of Virginia
  • Nautical Advisory Shares Buyer Perspective in Forbes Agency Council Webinar for Agency Founders
  • AdLeverage Brings Golf Simulator Contest and Home Services Marketing Expertise to Service World Expo 2026
  • Cleveland Factory Worker Seeks Funding for AI-Readable Archive Exploring Advanced AI Restraint and Human Survival
  • TradeJARnal Launches Innovative Trading Journal to Help Stock and Options Traders Build Discipline and Smarter Trading Habits
  • Pursant Founder Mark Herbick Joins STS Capital Partners as CEO
  • Tampa Holiday Sessions: Captured by Mallary Opens 2026 Christmas Minis With Two New Sets
  • Tampa Web Design Launches New Website for Entrepreneur and Capital Markets Advisor Martin Sumichrast
  • Miami Dade College and World Affairs Council of Miami announce Navarro-Cabrera scholarship
  • Nious Media Releases Debbie Bishop Interview on AI, Creativity, and Entertainment
  • RPP to host first Professional Padel Week in Miami and announce the 2026 USA Awards winners
  • UK Financial Ltd. Announces Maya Preferred PRA as First Fully Verified Asset on MAYA CHAIN; Chainlink Proof of Reserve Integration Planned for Network
  • ALight Technology And Services Limited Advances Through Peachscore + Dealum Accelerator and Join LvlUp Labs
  • International Misophonia Foundation Launches Sensory Accessible Technology Initiative to Address Overlooked Digital Accessibility Barriers
_catLbl0 _catLbl1

Popular on ncarol.com

  • Constantine "Costa" Kapothanasis II Acquires The Lubri-Loy Company, Carrying a 77-Year-Old American Lubricant Brand Into Its Next Era - 237
  • LowSignalMail Lets Users Handle Gmail by Text Message - 217
  • Parade of Homes Winners Announced - 216
  • North Carolina Author Carrie Sybert Celebrates Three Published Books - 177
  • Nious Media Expands Independent Entertainment Network Through Gaming, Music and Digital Storytelling - 172
  • LCM Company Explains Professional Upholstery Cleaning in Charlotte, NC - 146
  • B Street Productions Announces Red Carpet Premiere Of Thriller "a Deadly Proposal" In North Car - 130
  • Air Force Veteran Sean Douglas Delivers Powerful Suicide Prevention Presentations to Hundreds of Marines at Camp Pendleton - 112
  • Renew Integrative Health Publishes Updated Peptide Therapy Guide to Help Patients Understand Their Options - 108
  • 450 Million Revenue Run Rate, Global Telecom Reach and a New Digital Growth Opportunity Take Center Stage: IQSTEL, Inc. (N A S D A Q: IQST) - 107

Similar on ncarol.com

  • New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
  • Kestrel Ridge Health Launches AI-Powered Ophthalmology Workforce Forecasting Platform
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
  • New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
  • New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)
  • Longevity Academy Features Gail Humble, MD of KLOTHO SKIN in the Longevity Leaders Project
  • Expanding Into Medically Supervised Wellness With Major Apollo Wellness Centers Announcement; Sibannac, Inc. (Stock Symbol: SNNC)
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute